Compare
Cryo Cell International Inc vs Viemed Healthcare, Inc. vs Sotera Health Co vs Progyny, Inc.
| Latest fiscal year | Cryo Cell International Inc CCEL | Viemed Healthcare, Inc. VMD | Sotera Health Co SHC | Progyny, Inc. PGNY |
|---|---|---|---|---|
| Year ended | 2025-11-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $31.57M | $270.28M | $1.16B | $1.29B |
| Revenue growth (YoY) | -1.3% | +20.5% | +5.7% | +10.4% |
| Gross margin | 76.6% (computed) | 57.5% | 55.5% | 23.6% |
| Operating margin | 1.5% | 8.5% | n/a | 6.6% |
| Net margin | -7.7% | 5.5% | 6.7% | 4.5% |
| Net income | -$2.43M | $14.93M | $77.95M | $58.52M |
| EPS (Diluted) | -$0.30 | $0.37 | $0.27 | $0.65 |
| Operating cash flow | $5.48M | $51.92M | $287.19M | $210.19M |
| Free cash flow | $5.25M | $11.93M | $149.18M | $191.78M |
| Cash & equivalents | $319.0K | $13.50M | $344.62M | $112.24M |
| Total assets | $61.73M | $199.15M | $3.26B | $742.43M |
| Total liabilities | $80.33M | $55.63M | $2.66B | $226.39M |
| Shareholders' equity | -$18.61M | $141.54M | $606.03M | $516.04M |
| Return on year-end equity | n/a | 10.6% | 12.9% | 11.3% |
| Shares outstanding | 8.06M | 38.02M | n/a | 83.37M |
Revenue, most recent five fiscal years
| Fiscal year | Cryo Cell International Inc | Viemed Healthcare, Inc. | Sotera Health Co | Progyny, Inc. |
|---|---|---|---|---|
| Latest | $31.57M Ended 2025-11-30 | $270.28M Ended 2025-12-31 | $1.16B Ended 2025-12-31 | $1.29B Ended 2025-12-31 |
| 1 year earlier | $31.99M Ended 2024-11-30 | $224.26M Ended 2024-12-31 | $1.10B Ended 2024-12-31 | $1.17B Ended 2024-12-31 |
| 2 years earlier | $31.34M Ended 2023-11-30 | $183.01M Ended 2023-12-31 | $1.05B Ended 2023-12-31 | $1.09B Ended 2023-12-31 |
| 3 years earlier | $30.34M Ended 2022-11-30 | $138.83M Ended 2022-12-31 | $1.00B Ended 2022-12-31 | $786.91M Ended 2022-12-31 |
| 4 years earlier | $28.88M Ended 2021-11-30 | $117.06M Ended 2021-12-31 | $931.48M Ended 2021-12-31 | $500.62M Ended 2021-12-31 |